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  Background  The American Cancer Society, the Centers for Disease Control and Prevention (CDC), the National Cancer 
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually 
to provide updated information on cancer occurrence and trends in the United States. This year ’ s report includes 
trends in lung cancer incidence and death rates, tobacco use, and tobacco control by state of residence. 
  Methods  Information on invasive cancers was obtained from the NCI, CDC, and NAACCR and information on mor-
tality from the CDC’s National Center for Health Statistics. Annual percentage changes in the age- 
standardized incidence and death rates (2000 US population standard) for all cancers combined and for 
the top 15 cancers were estimated by joinpoint analysis of long-term (1975 – 2005) trends and by least 
squares linear regression of short-term (1996 – 2005) trends. All statistical tests were two-sided. 
  Results  Both incidence and death rates from all cancers combined decreased statistically significantly ( P < .05) in 
men and women overall and in most racial and ethnic populations. These decreases were driven largely 
by declines in both incidence and death rates for the three most common cancers in men (lung, colorec-
tum, and prostate) and for two of the three leading cancers in women (breast and colorectum), combined 
with a leveling off of lung cancer death rates in women. Although the national trend in female lung cancer 
death rates has stabilized since 2003, after increasing for several decades, there is prominent state and 
regional variation. Lung cancer incidence and/or death rates among women increased in 18 states, 16 of 
them in the South or Midwest, where, on average, the prevalence of smoking was higher and the annual 
percentage decrease in current smoking among adult women was lower than in the West and Northeast. 
California was the only state with decreasing lung cancer incidence and death rates in women. 
  Conclusions  Although the decrease in overall cancer incidence and death rates is encouraging, large state and regional 
differences in lung cancer trends among women underscore the need to maintain and strengthen many 
state tobacco control programs. 
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 The American Cancer Society, the Centers for Disease Control and 
Prevention (CDC), the National Cancer Institute (NCI), and the 
North American Association of Central Cancer Registries (NAACCR) 
collaborate each year to produce a report to the nation on the current 
status of the cancer burden in the United States. The first report, in 
1998, documented the first sustained decline in cancer death rates 
since the 1930s ( 1 ). Subsequent reports have updated information on 
trends in incidence and death rates and featured timely, in-depth 
analyses of selected topics ( 2 – 10 ). The current report provides 
updated trends in incidence and death rates for all cancers combined 
and the top 15 cancers among all races combined and in each of the 
four major racial and ethnic groups (white, black, Hispanic, and 
Asian and Pacific Islander [API]) by sex; it provides the mortality data 
for American Indian/Alaska Natives (AI/AN) who reside in counties 
that are covered by the Indian Health Service (IHS) Contract Health 
Service Delivery Area (CHSDA). This report also highlights emerg-
ing patterns in lung cancer, tobacco use, and tobacco control at the 
state and regional levels. 
jnci.oxfordjournals.org   JNCI |  Special Article 1673
 Subjects and Methods 
 Cancers, Cancer Deaths, and Population Estimates 
 Information on newly diagnosed invasive cancers, including 
in situ cancers of the bladder, was obtained from population-based 
cancer registries that participate in the NCI’s Surveillance, 
Epidemiology, and End Results (SEER) Program and/or the 
CDC’s National Program of Cancer Registries (NPCR). All can-
cer registries are members of NAACCR. 
 For incident cancers, site and histology were coded according 
to the International Classifi cation of Diseases for Oncology 
(ICD-O) edition in use at the time of diagnosis, converted to the 
Third Edition coding ( 11 ), and categorized according to SEER site 
groups ( 12 ). For cancer deaths, the underlying causes of death were 
selected according to the version of the International Classifi cation 
of Diseases (ICD) codes and selection rules in use at the time of 
death (ICD-6 – ICD-10) ( 13 – 17 ). Cause of death is based on the 
death certifi cate information reported to state vital statistics offi ces, 
which is consolidated through the CDC National Vital Statistics 
System ( 18 ) and categorized according to SEER site groups ( 12 ) to 
maximize comparability among ICD versions. County-level popu-
lation estimates, which were summed to the state and national 
level, were used as denominators in the rate calculations ( 19 ). 
Because the 2000 census allowed respondents to identify them-
selves as multiracial, the CDC National Center for Health 
Statistics and the Census Bureau developed methods for bridging 
multiple-race population estimates to single-race estimates to 
describe long-term trends in disease rates by race ( 20 ). The Census 
Bureau has provided the NCI with bridged, single-race annual 
population estimates from 1990 through 2005, with annual reesti-
mates calculated back to the most recent decennial census. The 
NCI makes slight modifi cations to the Hawaii population esti-
mates based on additional local information ( http://seer.cancer.
gov/popdata/methods.html ). In 2006, the Census Bureau improved 
its estimating methodologies; this affected the most recent set of 
population estimates (2000 – 2006) for some age groups in several 
states but not the estimate for the total US population (L. Sink, 
MS, Bureau of Census, personal communication, 2008). 
 In general, July 1 population estimates were used to calculate 
annual incidence and death rates because these estimates are con-
sidered to refl ect the average population of a defi ned geographic 
area for a calendar year. However, the populations of many coun-
ties along the Gulf Coast of Louisiana, Alabama, Mississippi, and 
Texas were displaced in the fall of 2005 by hurricanes Katrina and 
Rita. For these states, incidence data for the fi rst 6 months of 2005 
and half of the July 1 population estimate were used to calculate 
state-specifi c incidence rates for 2005. For the 2005 death rate 
calculations, the NCI made adjustments to the 2005 population 
estimates to account for the displacement. The national total 
population estimates are not affected by these adjustments. Further 
details on these calculations are provided at  http://seer.cancer.gov/
popdata/methods.html . 
 Incidence data are not uniformly available for every period, geo-
graphic area, and racial and ethnic group in the United States. 
Therefore, analyses of long-term (1975 – 2005) and short-term 
(1996 – 2005) trends in incidence rates and of average rates in defi ned 
periods (2001 – 2005) for the top 15 cancer sites pertain to different 
geographic areas and populations. Data from the nine original SEER 
areas (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
San Francisco – Oakland, Seattle – Puget Sound, and Utah), which 
cover about 10% of the US population (9% of US white and US 
black, 8% of US Hispanic, and 19% of US Asian) ( 21 ), were used to 
evaluate the long-term trends in incidence (1975 – 2005) for all races 
and ethnicities combined. Data from 29 population-based cancer 
registries were used to assess short-term trends (1996 – 2005), and 
data from 41 population-based cancer registries were used to esti-
mate average annual (2001 – 2005) age-standardized incidence rates 
for all races and ethnicities combined and for the four major racial 
and ethnic populations (white, black, API, and Hispanic). The 29 
and 41 registries met NAACCR’s data quality criteria for every year 
that was included in the analysis; they cover about 65% and 80% of 
the US population, respectively. The 29 cancer registries represent 
66% of the US white population, 58% black, 86% Hispanic, and 
84% Asian; the 41 cancer registries represent 81% of the US white 
population, 76% black, 91% Hispanic, and 90% Asian. 
 Similarly, mortality data from the National Center for Health 
Statistics were not available for every racial and ethnic group for 
all periods studied. For all races and ethnicities combined, we 
could examine long-term (1975 – 2005) and short term (1996 – 2005) 
trends and 5-year average annual age-standardized rates (2001 –
 2005) for all sites and the top 15 cancer sites. For each of the fi ve 
major racial and ethnic populations (white, black, API, AI/AN, and 
Hispanic), we present short-term trends (1996 – 2005) and 5-year 
average annual age-standardized rates (2001 – 2005). However, the 
mortality data for the AI/AN population were based on counties 
served by the IHS CHSDA, because estimated rates based on 
CHSDA counties have been reported to be more reliable ( 10 ). 
Mortality data presented in this report for AI/AN men and women 
therefore refer to those residing in CHSDA counties. At the time 
this report was written, linkage of new incident cases with IHS 
was incomplete and thus these data were not included. 
 Lung Cancer, Tobacco Use, and Tobacco Control 
Measures 
 We defined lung cancer as cancers of the lung and bronchus, 
except in the age-specific lung cancer mortality analysis, which 
includes data before the late 1950s, when “lung, pleura, bronchus 
and trachea” were combined in the standard mortality coding sys-
tem (ICD-6). We present short-term trends (1996 – 2005) and 
average annual age-standardized lung cancer incidence and death 
rates (2001 – 2005) for men and women of all races and ethnicities 
combined by state. Corresponding state-specific lung cancer death 
rates and trends for black and non-Hispanic white men and women 
are given in  Supplementary Table 1 (available online). 
 Information on adult cigarette smoking prevalence from 1997 
through 2006 by state and region was obtained from the CDC 
Behavioral Risk Factor Surveillance System (BRFSS) ( 22 ). We 
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chose to examine smoking prevalence data beginning in 1997 
because of a change on the assessment of smoking status on the 
BRFSS questionnaire in 1997 ( 22 ). Prevalence of cigarette use in 
the past month among youth aged 12 – 17 for 2004 – 2005 was 
abstracted from the Substance Abuse and Mental Health Services 
Administration’s National Survey on Drug Use and Health ( 23 ). 
Total federal and state tobacco tax and tobacco prevention spend-
ing as a percentage of the CDC minimum spending for comprehen-
sive tobacco control program by state were abstracted from 
Campaign for Tobacco-Free Kids ( 24 ). Trends in the initiation of 
established smoking (using the adult smoking defi nition of ever 
smoking 100 cigarettes and now smoking every day or some days) 
among adolescents aged 12 – 17 years were based on the NCI and 
CDC cosponsored series of Tobacco Use Supplements to the 
Current Population Survey (TUS-CPS) ( 25 ), which was updated 
from data previously published in NCI’s  Smoking and Tobacco 
Control Monograph 14 ( 26 ). 
 Statistical Analysis 
 Long-term trends (1975 – 2005) in age-standardized cancer incidence 
and death rates were described using joinpoint regression analysis, 
which involves fitting a series of joined straight lines on a logarith-
mic scale to the trends in the annual age-standardized rates ( 27 ). 
Beginning with this year’s annual report, we allowed a maximum of 
four rather than three joinpoints in the model because the additional 
joinpoint allowed better characterization of emerging trends. The 
method is described in detail elsewhere ( 27 ). The resulting trends of 
varying time periods were described by annual percent change 
(APC), ie, the slope of the line segment ( 27 ). We present long-term 
incidence trends that were based on both the observed data and data 
adjusted for reporting delay (which mostly affects recent years) ( 28 ). 
Descriptions of long-term trends in incidence were based on the 
delay-adjusted data, except when specifically noted. 
 For the short-term (1996 – 2005) trend analyses, the APC was 
estimated by fi tting a weighted least squares linear regression to 
the natural logarithms of the age-standardized rates using calendar 
year as the independent variable. In describing both long-term and 
short-term trends, the terms “increase” or “decrease” were used 
when the slope (APC) of the trend was statistically signifi cant ( P < 
.05); otherwise, the terms “stable” or “level” were used. 
 Trends in 5-year age-specifi c lung cancer incidence beginning 
at ages 30 – 34 for men and women were described using a semi-
logarithmic scale by year of diagnosis (1975 – 2005) and averaged 
over 2 consecutive years to improve stability. The same method 
was used to describe trends in 5-year age-specifi c lung cancer 
deaths by single year of death (1950 – 2005) and by year of birth 
(1860 – 1970). Birth cohort years were calculated by subtracting the 
age at death (middle of the 5-year age interval) from the calendar 
year of death (middle of the 5-year calendar period). The last time 
interval in the birth cohort analyses covered 6 years (2000 – 2005), 
but we assumed that the last year improved stability of the 5-year 
(2000 – 2004) estimate without affecting the average. Age-specifi c 
and age-standardized (2000 US standard population) rates were 
expressed per 100 000 population and generated using SEER*Stat 
Software, Version 6.3 ( http://www.seer.cancer.gov/seerstat/ ) ( 29 ). 
Rates (2001 – 2005) were suppressed when they were based on 
fewer than 16 observations. Similarly, the APC statistic was 
suppressed if a rate was based on fewer than 10 cancers in any one 
of the years within the designated time interval. 
 Weighted BRFSS data (by age, sex, and race and ethnicity) for 
each state were used to generate adult smoking prevalence esti-
mates using SUDAAN  statistical software to account for the com-
plex sampling design ( 30 ). The APC in smoking prevalence for 
each state and region from 1997 through 2006 was estimated using 
linear logistic regression, with the categorical variable (current 
smokers) as the dependent variable and year as a continuous inde-
pendent variable ( 31 ). 
 Results 
 Long-Term Incidence Trends for All Races Combined, 
1975 – 2005 
 Overall incidence rates for all racial and ethnic populations com-
bined decreased by 0.8% per year from 1999 through 2005 in both 
sexes combined, by 1.8% per year from 2001 through 2005 in men, 
and by 0.6% per year from 1998 through 2005 in women ( Table 1 ). 
Trends during the most recent periods (last joinpoint segments) for 
the top 15 cancers differed by sex. Among men, rates continued to 
decrease for lung and bronchus (lung), colon and rectal (colorectal), 
oral cavity and pharynx (oral cavity), and stomach cancers. For 
prostate cancer, rates decreased by 4.4% per year in the period 
2001 – 2005 after increasing by 2.1% annually from 1995 through 
2001. In contrast, rates increased for cancers of the kidney and 
renal pelvis (kidney), liver and intrahepatic bile duct (liver), 
and esophagus and for myeloma, non-Hodgkin lymphoma (NHL), 
and melanoma of the skin (melanoma). Incidence rates were stable 
for cancers of urinary bladder (bladder), pancreas, and brain and 
other nervous system (brain) and for leukemia. Among women, 
incidence rates decreased during the most recent joinpoint seg-
ments for six of the top 15 cancers (breast, colorectum, uterine 
corpus and uterus not otherwise specified [uterus], ovary, cervix 
uteri [cervix], and oral cavity and pharynx). Rates increased for the 
remaining nine of the top 15 cancers (lung, thyroid, pancreas, blad-
der, kidney, brain, NHL, melanoma, and leukemia). 
 Long-Term Mortality Trends for All Races Combined, 
1975 – 2005 
 Overall cancer death rates have continued to decrease since the 
early 1990s in both men and women ( Table 2 ). Death rates 
decreased by 1.5% per year from 1993 through 2001 and 2.0% per 
year from 2001 through 2005 in men and by 0.8% per year from 
1994 through 2002 and 1.6% per year from 2002 through 2005 in 
women. Among the top 15 causes of cancer death, death rates 
decreased for 10 cancer sites during the most recent period (last 
joinpoint segment) of the long-term trend in both men and 
women, although the sites were different: colorectum, stomach, 
kidney, brain, leukemia, NHL, and myeloma in both men and 
women; lung, prostate, and oral cavity and pharynx in men; and 
breast, uterine cervix, and bladder in women. Cancers with 
increasing mortality trends during the most recent period included 
esophageal cancer in men, pancreatic cancer in women, and liver 
cancer in both men and women. Death rates stabilized for cancers 
of the pancreas and bladder and for melanoma in men and for 
cancers of the lung, ovary, and uterus in women. 
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 Table 1 .  SEER cancer incidence rate trends with joinpoint analyses (up to four joinpoints allowed) for 1975 – 2005 for the top 15 cancers, 
by sex, for all races * 
 Sex/cancer site 
or type
Joinpoint analyses (1975 – 2005) † 
 Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 
 Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ 
 All sites §           
  Both sexes 1975 – 1989 1.2 || 1989 – 1992 2.8 1992 – 1995  – 2.2 1995 – 2001 0.4 2001 – 2005  – 1.7 || 
   Delay adjusted 1975 – 1989 1.2 || 1989 – 1992 2.8 || 1992 – 1995  – 2.4 1995 – 1999 0.9 1999 – 2005  – 0.8 || 
  Males 1975 – 1989 1.3 || 1989 – 1992 5.1 || 1992 – 1995  – 4.8 || 1995 – 2001 0.3 2001 – 2005  – 2.2 || 
   Delay adjusted 1975 – 1989 1.3 || 1989 – 1992 5.2 || 1992 – 1995  – 4.8 || 1995 – 2001 0.3 2001 – 2005  – 1.8 || 
  Females 1975 – 1979  – 0.3 1979 – 1987 1.6 || 1987 – 1995 0.1 1995 – 1998 1.5 1998 – 2005  – 0.8 || 
   Delay adjusted 1975 – 1979  – 0.3 1979 – 1987 1.6 || 1987 – 1995 0.1 1995 – 1998 1.4 1998 – 2005  – 0.6 || 
 Top 15 cancers for 
   males ¶ 
          
  Prostate 1975 – 1988 2.6 || 1988 – 1992 16.5 || 1992 – 1995  – 11.6 || 1995 – 2001 2.0 || 2001 – 2005  – 4.9 || 
   Delay adjusted 1975 – 1988 2.6 || 1988 – 1992 16.5 || 1992 – 1995  – 11.5 || 1995 – 2001 2.1 || 2001 – 2005  – 4.4 || 
  Lung and bronchus 1975 – 1982 1.4 || 1982 – 1991  – 0.4 1991 – 2005  – 1.9 ||     
   Delay adjusted 1975 – 1982 1.5 || 1982 – 1991  – 0.5 1991 – 2005  – 1.8 ||     
  Colon and rectum 1975 – 1985 1.1 || 1985 – 1991  – 1.2 || 1991 – 1995  – 3.2 || 1995 – 1998 2.0 1998 – 2005  – 3.0 || 
   Delay adjusted 1975 – 1985 1.1 || 1985 – 1991 1.2 || 1991 – 1995  – 3.1 || 1995 – 1998 1.9 1998 – 2005  – 2.8 || 
  Urinary bladder 1975 – 1987 0.9 || 1987 – 2005  – 0.1       
   Delay adjusted 1975 – 1986 0.9 || 1986 – 2005 0.0       
  Melanoma of the 
    skin
1975 – 1985 5.4 || 1985 – 2000 3.4 || 2000 – 2003  – 0.4 2003 – 2005 6.4   
   Delay adjusted 1975 – 1985 5.4 || 1985 – 2000 3.4 || 2000 – 2003  – 0.2 2003 – 2005 7.7 ||   
  Non-Hodgkin 
    lymphoma
1975 – 1991 4.2 || 1991 – 2005 0.2       
   Delay adjusted 1975 – 1991 4.2 || 1991 – 2005 0.4 ||       
  Kidney and renal 
    pelvis
1975 – 2005 1.7 ||         
   Delay adjusted 1975 – 2005 1.8 ||         
  Leukemia 1975 – 2001 0.0 2001 – 2005  – 2.2 ||       
   Delay adjusted 1975 – 2005 0.1         
  Oral cavity and 
    pharynx
1975 – 1983  – 0.2 1983 – 2005  – 1.4 ||       
   Delay adjusted 1975 – 2005  – 1.2 ||         
  Pancreas 1975 – 1993  – 0.9 || 1993 – 2005 0.3       
   Delay adjusted 1975 – 1993  – 0.9 || 1993 – 2005 0.4       
  Stomach 1975 – 1988  – 1.2 || 1988 – 2005  – 2.1 ||       
   Delay adjusted 1975 – 1988  – 1.2 || 1988 – 2005  – 2.0 ||       
  Liver and intrahepatic 
    bile duct
1975 – 1986 2.1 || 1986 – 1996 4.9 || 1996 – 2005 2.4 ||     
   Delay adjusted 1975 – 2005 3.6 ||         
  Esophagus 1975 – 2005 0.7 ||         
   Delay adjusted 1975 – 2005 0.7 ||         
  Brain and other 
    nervous system
1975 – 1991 1.1 || 1991 – 2005  – 0.7 ||       
   Delay adjusted 1975 – 1989 1.2 || 1989 – 2005  – 0.4       
  Myeloma 1975 – 1991 1.3 || 1991 – 2005 0.0       
   Delay adjusted 1975 – 2005 0.8 ||         
 Top 15 cancers for 
   females ¶ 
          
  Breast 1975 – 1980  – 0.5 1980 – 1987 4.0 || 1987 – 1992  – 0.2 1994 – 1999 1.7 || 1999 – 2005  – 2.4 || 
   Delay adjusted 1975 – 1980  – 0.6 1980 – 1987 4.0 || 1987 – 1994  – 0.2 1994 – 1999 1.7 || 1999 – 2005  – 2.2 || 
  Lung and bronchus 1975 – 1982 5.5 || 1982 – 1990 3.5 || 1990 – 1998 1.0 || 1998 – 2005  – 0.2   
   Delay adjusted 1975 – 1982 5.6 || 1982 – 1991 3.4 || 1991 – 2005 0.5 ||     
  Colon and rectum 1975 – 1985 0.3 1985 – 1995  – 1.9 || 1995 – 1998 1.9 1998 – 2005  – 2.4 ||   
   Delay adjusted 1975 – 1985 0.3 1985 – 1995  – 1.9 || 1995 – 1998 1.9 1998 – 2005  – 2.2 ||   
  Uterine corpus 
    and uterus NOS
1975 – 1979  – 6.0 || 1979 – 1988  – 1.7 || 1988 – 1997 0.7 || 1997 – 2005  – 0.6 ||   
   Delay adjusted 1975 – 1979  – 6.0 || 1979 – 1988  – 1.7 || 1988 – 1997 0.7 || 1997 – 2005  – 0.5 ||   
  Non-Hodgkin 
    lymphoma
1975 – 1990 2.9 || 1990 – 2005 1.0 ||       
(Table continues)
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 Sex/cancer site 
or type
Joinpoint analyses (1975 – 2005) † 
 Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 
 Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ 
   Delay adjusted 1975 – 1990 2.8 || 1990 – 2005 1.2 ||       
  Melanoma of the 
    skin
1975 – 1981 4.9 || 1981 – 2005 2.3 ||       
   Delay adjusted 1975 – 1981 5.7 || 1981 – 1993 1.9 || 1993 – 2005 2.9 ||     
  Thyroid 1975 – 1977 6.6 1977 – 1980  – 5.6 1980 – 1996 2.5 || 1996 – 2005 6.4 ||   
   Delay adjusted 1975 – 1977 6.7 1977 – 1980  – 6.0 1980 – 1997 2.7 || 1997 – 2005 6.9 ||   
  Ovary § 1975 – 1985 0.1 1985 – 2001  – 0.7 || 2001 – 2005  – 3.0 ||     
   Delay adjusted § 1975 – 1985 0.1 1985 – 2001  – 0.7 || 2001 – 2005  – 2.4 ||     
  Pancreas 1975 – 1983 1.3 || 1983 – 2005  – 0.1       
   Delay adjusted 1975 – 1984 1.5 || 1984 – 1994  – 0.6 1994 – 2005 0.6 ||     
  Leukemia 1975 – 2005 0.0         
   Delay adjusted 1975 – 2005 0.2 ||         
  Urinary bladder 1975 – 2005 0.1 ||         
   Delay adjusted 1975 – 2005 0.2 ||         
  Kidney and renal 
    pelvis
1975 – 2005 2.2 ||         
   Delay adjusted 1975 – 2005 2.3 ||         
  Uterine cervix 1975 – 1981  – 4.6 || 1981 – 1996  – 1.1 || 1996 – 2005  – 3.8 ||     
   Delay adjusted 1975 – 1981  – 4.6 || 1981 – 1996  – 1.1 || 1996 – 2005  – 3.6 ||     
  Oral cavity and 
    pharynx
1975 – 1980 2.6 || 1980 – 2005  – 1.0 ||       
   Delay adjusted 1975 – 1980 2.6 1980 – 2005  – 0.9 ||       
  Brain and other 
    nervous system
1975 – 1990 1.5 || 1990 – 1994  – 2.4 1994 – 2005 0.5     
   Delay adjusted 1975 – 1990 1.5 || 1990 – 1994  – 2.5 1994 – 2005 0.8 ||     
 *  SEER  =  Surveillance, Epidemiology, and End Results; APC  =  annual percent change; NOS  =  not otherwise specified. Source: SEER-9 areas covering about 10% 
of the US population (Connecticut, Hawaii, Iowa, Utah, and New Mexico, and the metropolitan areas of San Francisco-Oakland, Detroit, Atlanta, and Seattle-Puget 
Sound). Nonadjusted rates and rates that were adjusted for delays in reporting are shown. 
 †  Joinpoint analyses with up to four joinpoints were based on rates (per 100  000 persons) and were age adjusted to the 2000 US standard population. 
Joinpoint analysis used the Joinpoint Regression Program, Version 3.2.0. January 2008, National Cancer Institute. 
 ‡  APC is based on rates that were age standardized to the 2000 US standard population. 
 §  All sites excludes myelodysplastic syndromes and borderline tumors of the ovary; ovary excludes borderline tumors. 
 ||  APC is statistically significantly different from zero (two-sided  P < .05, calculated using a  t test). 
 ¶  The top 15 cancers were selected based on the sex-specific age-standardized incidence rates for 2001 – 2005 for all races combined and listed in rank order. 
Table 1 (continued).
 Cancer Incidence Rates, 2001 – 2005, and Short-Term 
Trends by Race and Ethnicity, 1996 – 2005 
 Black men had the highest cancer incidence rate for 2001 – 2005 
among all men, and white women had the highest rate among all 
women ( Table 3 ). The top three cancer sites were the same among 
all racial and ethnic populations studied, with some variation in 
rank order. Beyond the top three sites, race-specific rankings var-
ied substantially among racial and ethnic groups. 
 Incidence rates for all cancer sites combined decreased from 
1996 through 2005 in both men and women in all racial and ethnic 
populations ( Table 3 ). Among men, lung and colorectal cancer inci-
dence rates decreased for all populations. Prostate cancer incidence 
rates were stable in white, API, and Hispanic men but decreased in 
black men. Among women, breast and colorectal cancer incidence 
rates decreased for all race and ethnic groups, except for breast can-
cer in API women. Lung cancer incidence rates increased in white 
women but were stable in the other populations. Kidney and liver 
cancer incidence rates increased in both men and women of all racial 
and ethnic groups except for liver cancer in API and Hispanic 
women and both kidney and liver cancer in API men. 
 Cancer Death Rates, 2001 – 2005, and Short-Term Trends 
by Race and Ethnicity, 1996 – 2005 
 Death rates for all cancers combined (2001 – 2005) were highest for 
blacks and lowest for API men and women ( Table 4 ). Cancers of the 
lung, prostate, and colorectum were the three leading causes of 
cancer death in rank order among men for each major racial and 
ethnic population, except API men, in whom cancer of the liver 
ranked second. The corresponding leading sites of cancer death in 
rank order among women were lung, breast, and colorectum, except 
among Hispanic women in whom breast cancer ranked first. After 
the top three sites, race-specific rankings varied for both sexes. 
 From 1996 through 2005, death rates for all cancers com-
bined decreased for all racial and ethnic populations and in both 
men and women, except the rates for AI/AN men and women, 
which were stable. Similarly, death rates for cancers of the lung, 
prostate, and colorectum in men decreased for all racial and eth-
nic populations, except prostate and colorectal cancer in AI/AN 
men. Breast cancer death rates decreased in white, black, and 
Hispanic women but were stable in API and AI/AN women. 
Colorectal cancer death rates decreased for white, black, and API 
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 Table 2 .  US cancer death rate trends with joinpoint analyses (up to four joinpoints allowed) for 1975 – 2005 for the top 15 cancers, by sex, 
for all races * 
 Sex/cancer site or type
Joinpoint analyses (1975 – 2005) † 
 Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 
 Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ Years APC ‡ 
 All sites           
  Both sexes 1975 – 1990 0.5 § 1990 – 1993  – 0.3 1993 – 2002  – 1.1 § 2002 – 2005  – 1.8 §   
  Males 1975 – 1979 1.0 § 1979 – 1990 0.3 § 1990 – 1993  – 0.5 1993 – 2001  – 1.5 § 2001 – 2005  – 2.0 § 
  Females 1975 – 1990 0.6 § 1990 – 1994  – 0.2 1994 – 2002  – 0.8 § 2002 – 2005  – 1.6 §   
 Top 15 cancers for males ||           
  Lung and bronchus 1975 – 1978 2.5 § 1978 – 1984 1.2 § 1984 – 1990 0.4 § 1990 – 1993  – 1.1 1993 – 2005  – 1.9 § 
  Prostate 1975 – 1987 0.9 § 1987 – 1991 3.0 § 1991 – 1994  – 0.6 1994 – 2005  – 4.1 §   
  Colon and rectum 1975 – 1978 0.8 1978 – 1984  – 0.4 1984 – 1990  – 1.3 § 1990 – 2002  – 2.0 § 2002 – 2005  – 4.3 § 
  Pancreas 1975 – 1986  – 0.8 § 1986 – 2003  – 0.3 § 2003 – 2005 1.3     
  Leukemia 1975 – 1995  – 0.2 § 1995 – 2005  – 0.8 §       
  Non-Hodgkin lymphoma 1975 – 1991 2.7 § 1991 – 1997 1.6 § 1997 – 2005  – 3.0 §     
  Esophagus 1975 – 1985 0.7 § 1985 – 1994 1.2 § 1994 – 2005 0.4 §     
  Urinary bladder 1975 – 1983  – 1.4 § 1983 – 1987  – 2.7 § 1987 – 1993 0.1 1993 – 2003  – 0.7 § 2003 – 2005 1.1 
  Liver and intrahepatic 
   bile duct
1975 – 1979 0.3 1979 – 1987 2.3 § 1987 – 1996 3.9 § 1996 – 1999 0.4 1999 – 2005 2.6 § 
  Kidney and renal pelvis 1975 – 1992 1.1 § 1992 – 2005  – 0.3 §       
  Stomach 1975 – 1994  – 2.1 § 1994 – 2005  – 3.7 §       
  Brain and other nervous 
   system
1975 – 1977 4.3 1977 – 1982  – 0.3 1982 – 1991 1.3 § 1991 – 2005  – 0.9 §   
  Myeloma 1975 – 1994 1.5 § 1994 – 2005  – 1.0 §       
  Oral cavity and pharynx 1975 – 1980  – 0.9 1980 – 2005  – 2.2 §       
  Melanoma of the skin 1975 – 1990 2.2 § 1990 – 2005 0.1       
 Top 15 cancers for 
  females || 
          
  Lung and bronchus 1975 – 1982 6.0 § 1982 – 1990 4.2 § 1990 – 1995 1.7 § 1995 – 2003 0.3§ 2003 – 2005  – 0.9 
  Breast 1975 – 1990 0.4§ 1990 – 1995  – 1.8 § 1995 – 1998  – 3.3 § 1998 – 2005  – 1.8 §   
  Colon and rectum 1975 – 1984  – 1.0 § 1984 – 2002  – 1.8 § 2002 – 2005  – 4.3 §     
  Pancreas 1975 – 1984 0.8 § 1984 – 2005 0.1 §       
  Ovary 1975 – 1982  – 1.2 § 1982 – 1992 0.3 § 1992 – 1998  – 1.2 § 1998 – 2002 0.8 2002 – 2005  – 1.5 
  Non-Hodgkin lymphoma 1975 – 1995 2.2 § 1995 – 1998  – 0.3 1998 – 2005  – 3.7 §     
  Leukemia 1975 – 1980 0.8 1980 – 2001  – 0.4 § 2001 – 2005  – 2.2 §     
  Uterine corpus and 
   uterus NOS
1975 – 1991  – 1.6 § 1991 – 2005  – 0.1       
  Brain and other nervous 
   system
1975 – 1992 0.9 § 1992 – 2005  – 1.0 §       
  Liver and intrahepatic 
   bile duct
1975 – 1978  – 1.5 1978 – 1988 1.4 § 1988 – 1995 3.9 § 1995 – 2001 0.3 2001 – 2005 2.1 § 
  Myeloma 1975 – 1993 1.5 § 1993 – 2001  – 0.4 2001 – 2005  – 2.5 §     
  Stomach 1975 – 1987  – 2.8§ 1987 – 1990  – 0.4 1990 – 2005  – 2.7 §     
  Kidney and renal pelvis 1975 – 1992 1.3 § 1992 – 2005  – 0.5 §       
  Uterine cervix 1975 – 1982  – 4.4 § 1982 – 1995  – 1.6 § 1995 – 2005  – 3.4 §     
  Urinary bladder 1975 – 1986  – 1.7 § 1986 – 2005  – 0.4 §       
 *  APC  =  annual percent change; NOS  =  not otherwise specified. Source: National Center for Health Statistics, 2005 Mortality Special Research File. 
 †  Joinpoint analyses with up to four joinpoints were based on rates (per 100  000 persons) and were age standardized to the 2000 US standard population. 
Joinpoint Regression Program, Version 3.2.0. January 2008, National Cancer Institute. 
 ‡  APC is based on rates that were age standardized to the 2000 US standard population. 
 §  APC is statistically significantly different from zero (two-sided  P < .05, calculated using a  t test). 
 ||  The top 15 cancers were selected based on the sex-specific age-standardized death rates for 2001 – 2005 for all races combined and listed in rank order. 
women but not for Hispanic and AI/AN women. Lung cancer 
death rates were stable in all populations, except AI/AN, in 
whom they increased. Liver cancer death rates increased in white 
and Hispanic men and women and in black men but decreased 
for API men and remained stable for the other race and ethnicity 
and sex groups. Esophageal cancer death rates increased for 
white and AI/AN men but decreased for black and Hispanic men 
and women. Death rates for pancreatic cancer increased in white 
men and women but decreased in black men and women. 
Cervical cancer death rates decreased for women of all races 
except AI/AN. 
 Trends in Lung Cancer, Tobacco Use, and Tobacco 
Control 
 We present the trends in age-standardized lung cancer incidence 
and death rates for men and women of all races combined from 
1678   Special Article | JNCI Vol. 100, Issue 23  |  December 3, 2008
 T
ab
le
 3
  .    I
n
ci
d
en
ce
 r
at
es
 f
o
r 
20
01
 – 2
00
5 
an
d
 s
h
o
rt
-t
er
m
 t
re
n
d
s 
fo
r 
19
96
 – 2
00
5 
fo
r 
th
e 
to
p
 1
5 
ca
n
ce
rs
 b
y 
se
x,
 r
ac
e,
 a
n
d
 e
th
n
ic
it
y,
 s
el
ec
te
d
 a
re
as
 in
 t
h
e 
U
n
it
ed
 S
ta
te
s *
   
  S
ex
/c
an
ce
r 
si
te
 o
r 
ty
p
e  †
  
A
ll 
ra
ce
s/
et
h
n
ic
it
ie
s
W
h
it
e  ‡
  
B
la
ck
  ‡  
A
P
I  ‡
  
H
is
p
an
ic
  ‡   
 R
an
k
R
at
e§
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||    
  M
al
es
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 A
ll 
si
te
s ¶
 
0
56
2.
3
 – 0
.8
  #  
0
55
6.
9
 – 0
.8
  #  
0
63
5.
6
 – 1
.6
  #  
0
34
0.
1
 – 1
.4
  #  
0
44
0.
1
 – 1
.0
  #   
    
 P
ro
st
at
e
1
15
8.
3
 – 1
.1
1
14
9.
8
 – 1
.3
1
23
6.
0
 – 1
.6
  #  
1
84
.7
 – 1
.1
1
13
4.
9
 – 1
.2
 
    
 Lu
ng
 a
nd
 b
ro
nc
hu
s
2
87
.3
 – 1
.9
  #  
2
86
.9
 – 1
.7
  #  
2
10
6.
8
 – 2
.9
  #  
2
51
.9
 – 1
.7
  #  
3
50
.9
 – 2
.4
  #   
    
 C
ol
on
 a
nd
 r
ec
tu
m
3
61
.2
 – 2
.1
  #  
3
60
.6
 – 2
.2
  #  
3
69
.4
 – 1
.0
  #  
3
45
.5
 – 2
.2
  #  
2
51
.5
 – 1
.0
  #   
    
 U
rin
ar
y 
bl
ad
de
r
4
38
.4
 – 0
.2
4
40
.6
 – 0
.2
5
18
.7
 – 0
.2
6
15
.3
0.
1
4
21
.6
 – 0
.5
 
    
 N
on
-H
od
gk
in
 ly
m
ph
om
a
5
23
.2
0.
0
6
23
.7
0.
0
7
17
.2
 – 0
.6
7
15
.0
 – 0
.6
5
19
.7
 – 0
.7
 
    
 M
el
an
om
a 
of
 t
he
 s
ki
n
6
22
.0
2.
9  #
  
5
24
.2
2.
9  #
  
24
1.
1
 – 4
.0
  #  
19
1.
5
1.
1
16
4.
5
0.
9 
    
 K
id
ne
y 
an
d 
re
na
l p
el
vi
s
7
19
.1
2.
5  #
  
7
19
.3
2.
5  #
  
4
20
.0
2.
9  #
  
11
8.
7
1.
2
6
17
.9
2.
6  #
   
    
 Le
uk
em
ia
8
16
.2
 – 0
.7
8
16
.6
 – 0
.7
12
12
.3
 – 1
.0
  #  
10
8.
8
 – 1
.3
9
12
.0
 – 1
.1
 
    
 O
ra
l c
av
ity
 a
nd
 p
ha
ry
nx
9
16
.1
 – 1
.0
  #  
9
16
.0
 – 0
.7
  #  
6
17
.3
 – 3
.2
  #  
8
10
.5
 – 2
.5
  #  
11
11
.0
 – 2
.7
  #   
    
 P
an
cr
ea
s
10
13
.0
0.
4  #
  
10
12
.8
0.
5  #
  
9
16
.0
 – 0
.5
9
9.
3
 – 0
.5
10
11
.3
0.
0 
    
 S
to
m
ac
h
11
10
.3
 – 2
.4
  #  
11
9.
3
 – 2
.5
  #  
8
17
.1
 – 3
.2
  #  
5
18
.3
 – 2
.8
  #  
8
15
.0
 – 2
.3
  #   
    
 Li
ve
r 
an
d 
in
tr
ah
ep
at
ic
 b
ile
 d
uc
t
12
8.
8
3.
3  #
  
14
7.
8
3.
4  #
  
11
12
.5
4.
1  #
  
4
21
.5
 – 0
.4
7
15
.6
2.
3  #
   
    
 E
so
ph
ag
us
13
8.
6
0.
3
12
8.
5
1.
2  #
  
14
11
.0
 – 5
.8
  #  
13
4.
0
 – 3
.9
  #  
15
5.
7
 – 1
.2
  #   
    
 B
ra
in
 a
nd
 o
th
er
 n
er
vo
us
 s
ys
te
m
14
7.
9
 – 0
.5
  #  
13
8.
4
 – 0
.5
  #  
15
4.
7
 – 0
.2
13
4.
0
 – 1
.8
14
6.
3
0.
4 
    
 La
ry
nx
15
7.
3
 – 3
.2
  #  
15
7.
0
 – 3
.0
  #  
13
11
.4
 – 3
.4
  #  
16
2.
7
 – 4
.5
  #  
13
6.
4
 – 4
.0
  #   
    
 M
ye
lo
m
a
16
7.
0
 – 0
.3
16
6.
5
 – 0
.4
10
13
.3
0.
3
15
3.
6
 – 3
.5
  #  
12
6.
6
 – 0
.1
 
    
 Th
yr
oi
d
18
4.
6
5.
8  #
  
18
4.
8
5.
8  #
  
19
2.
6
5.
2  #
  
12
4.
2
3.
4  #
  
17
3.
7
4.
9  #
   
 Fe
m
al
es
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 A
ll 
si
te
s ¶
 
0
41
7.
3
 – 0
.4
  #  
0
42
3.
4
 – 0
.4
  #  
0
38
9.
9
 – 0
.5
  #  
0
27
6.
3
 – 0
.5
  #  
0
33
1.
7
 – 0
.5
  #   
    
 B
re
as
t
1
12
3.
6
 – 1
.3
  #  
1
12
5.
9
 – 1
.3
  #  
1
11
1.
5
 – 0
.6
  #  
1
81
.6
 – 0
.2
1
91
.3
 – 0
.9
  #   
    
 Lu
ng
 a
nd
 b
ro
nc
hu
s
2
55
.4
0.
2
2
57
.0
0.
3  #
  
3
51
.1
 – 0
.1
3
27
.3
 – 0
.2
3
27
.2
 – 0
.2
 
    
 C
ol
on
 a
nd
 r
ec
tu
m
3
44
.8
 – 1
.7
  #  
3
44
.0
 – 1
.8
  #  
2
52
.4
 – 1
.0
  #  
2
33
.6
 – 1
.4
  #  
2
36
.2
 – 1
.2
  #   
    
 U
te
rin
e 
co
rp
us
 a
nd
 u
te
ru
s 
N
O
S
4
23
.8
 – 0
.2
4
24
.4
 – 0
.4
4
20
.6
1.
1  #
  
4
15
.2
1.
1  #
  
4
19
.0
1.
0  #
   
    
 N
on
-H
od
gk
in
 ly
m
ph
om
a
5
16
.3
0.
3
5
16
.8
0.
2
7
11
.5
0.
7  #
  
6
10
.7
0.
0
5
15
.0
0.
1 
    
 M
el
an
om
a 
of
 t
he
 s
ki
n
6
14
.2
3.
4  #
  
6
16
.0
3.
5  #
  
28
1.
0
 – 0
.3
21
1.
3
2.
3
17
4.
3
1.
7  #
   
    
 Th
yr
oi
d
7
13
.4
7.
1  #
  
7
13
.9
7.
2  #
  
12
8.
2
7.
1  #
  
5
13
.4
4.
6  #
  
7
13
.0
6.
2  #
   
    
 O
va
ry
 ¶
 
8
13
.3
 – 1
.7
  #  
8
13
.8
 – 1
.8
  #  
8
10
.1
 – 0
.9
8
9.
4
 – 1
.5
  #  
8
11
.7
 – 0
.7
 
    
 P
an
cr
ea
s
9
10
.1
0.
6  #
  
12
9.
8
0.
7  #
  
5
13
.4
 – 0
.1
10
7.
9
0.
3
10
9.
8
0.
3 
    
 K
id
ne
y 
an
d 
re
na
l p
el
vi
s
10
9.
8
2.
8  #
  
10
10
.0
2.
9  #
  
8
10
.1
2.
7  #
  
14
4.
3
2.
6  #
  
9
10
.0
2.
1  #
   
    
 U
rin
ar
y 
bl
ad
de
r
10
9.
8
 – 0
.3
9
10
.3
 – 0
.2
14
6.
9
 – 0
.8
15
4.
0
 – 0
.2
14
5.
9
 – 0
.5
 
    
 Le
uk
em
ia
12
9.
7
 – 0
.5
11
9.
9
 – 0
.5
13
7.
8
 – 1
.0
12
5.
6
 – 1
.3
12
8.
3
 – 0
.5
 
    
 U
te
rin
e 
ce
rv
ix
13
8.
5
 – 3
.7
  #  
13
8.
1
 – 3
.5
  #  
6
11
.9
 – 5
.0
  #  
11
7.
8
 – 5
.3
  #  
6
13
.4
 – 4
.2
  #   
(T
ab
le
 c
on
tin
ue
s)
jnci.oxfordjournals.org   JNCI |  Special Article 1679
  S
ex
/c
an
ce
r 
si
te
 o
r 
ty
p
e  †
  
A
ll 
ra
ce
s/
et
h
n
ic
it
ie
s
W
h
it
e  ‡
  
B
la
ck
  ‡  
A
P
I  ‡
  
H
is
p
an
ic
  ‡   
 R
an
k
R
at
e§
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||  
R
an
k
R
at
e §
 
A
P
C
  ||    
    
 O
ra
l c
av
ity
 a
nd
 p
ha
ry
nx
14
6.
1
 – 1
.2
  #  
14
6.
1
 – 1
.1
  #  
15
5.
6
 – 2
.3
  #  
13
5.
3
 – 0
.7
18
4.
0
 – 2
.2
  #   
    
 B
ra
in
 a
nd
 o
th
er
 n
er
vo
us
 s
ys
te
m
15
5.
7
 – 0
.4
  #  
14
6.
1
 – 0
.3
17
3.
6
 – 1
.0
16
3.
1
0.
1
16
4.
8
 – 1
.2
  #   
    
 S
to
m
ac
h
16
5.
0
 – 1
.3
  #  
16
4.
3
 – 1
.4
  #  
11
8.
8
 – 2
.0
  #  
7
10
.2
 – 3
.3
  #  
11
8.
8
 – 1
.2
 
    
 M
ye
lo
m
a
17
4.
6
 – 0
.6
  #  
17
4.
1
 – 0
.8
  #  
10
9.
5
 – 0
.7
17
2.
7
 – 2
.2
  #  
15
4.
9
 – 0
.2
 
    
 Li
ve
r 
an
d 
in
tr
ah
ep
at
ic
 b
ile
 d
uc
t
18
3.
1
1.
3  #
  
18
2.
7
0.
9  #
  
16
3.
8
2.
1  #
  
9
8.
0
0.
1
13
6.
0
0.
7  
  *  
 A
P
I   =
   A
si
an
/P
ac
ifi
c 
Is
la
nd
er
; A
P
C
   =
   a
nn
ua
l p
er
ce
nt
 c
ha
ng
e;
 N
O
S
   =
   n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; S
E
E
R
   =
   S
ur
ve
ill
an
ce
, E
pi
de
m
io
lo
gy
, a
nd
 E
nd
 R
es
ul
ts
; N
P
C
R
   =
   N
at
io
na
l P
ro
gr
am
 o
f 
C
an
ce
r 
R
eg
is
tr
ie
s;
 N
A
A
C
C
R
   =
   N
or
th
 
A
m
er
ic
an
 A
ss
oc
ia
tio
n 
of
 C
en
tr
al
 C
an
ce
r 
R
eg
is
tr
ie
s.
 S
ou
rc
e:
 S
E
E
R
 a
nd
 N
P
C
R
 a
re
as
 r
ep
or
te
d 
by
 N
A
A
C
C
R
 a
s 
m
ee
tin
g 
hi
gh
-q
ua
lit
y 
da
ta
 s
ta
nd
ar
ds
 f
or
 t
he
 s
pe
ci
fie
d 
tim
e 
pe
rio
ds
.  
   †   
 C
an
ce
rs
 a
re
 s
or
te
d 
in
 d
es
ce
nd
in
g 
or
de
r a
cc
or
di
ng
 to
 s
ex
-s
pe
ci
fic
 ra
te
s 
fo
r a
ll 
ra
ce
s 
an
d 
et
hn
ic
iti
es
. M
or
e 
th
an
 1
5 
ca
nc
er
s 
m
ay
 a
pp
ea
r u
nd
er
 m
al
es
 a
nd
 fe
m
al
es
 to
 in
cl
ud
e 
th
e 
to
p 
15
 c
an
ce
rs
 in
 e
ve
ry
 ra
ce
 a
nd
 e
th
ni
ci
ty
 
gr
ou
p.
  
   ‡   
 W
hi
te
, b
la
ck
, a
nd
 A
P
I i
nc
lu
de
 H
is
pa
ni
c 
an
d 
no
n-
H
is
pa
ni
c;
 t
he
 r
ac
e 
an
d 
et
hn
ic
ity
 c
at
eg
or
ie
s 
ar
e 
no
t 
m
ut
ua
lly
 e
xc
lu
si
ve
.  
  §  
 R
at
es
 (p
er
 1
00
   0
00
 p
er
so
ns
) w
er
e 
ag
e 
st
an
da
rd
iz
ed
 t
o 
th
e 
20
00
 U
S
 s
ta
nd
ar
d 
po
pu
la
tio
n.
 2
00
1 –
 20
05
 r
at
es
 f
or
 a
ll 
ra
ce
s 
an
d 
et
hn
ic
iti
es
, w
hi
te
, b
la
ck
, A
P
I, 
H
is
pa
ni
c,
 a
nd
 n
on
-H
is
pa
ni
c 
(4
0 
st
at
es
 a
nd
 D
is
tr
ic
t 
of
 
C
ol
um
bi
a)
: A
la
ba
m
a,
 A
la
sk
a,
 A
rk
an
sa
s,
 C
al
ifo
rn
ia
, C
ol
or
ad
o,
 C
on
ne
ct
ic
ut
, D
el
aw
ar
e,
 D
is
tr
ic
t 
of
 C
ol
um
bi
a,
 F
lo
rid
a,
 G
eo
rg
ia
, H
aw
ai
i, 
Id
ah
o,
 Il
lin
oi
s,
 In
di
an
a,
 Io
w
a,
 K
en
tu
ck
y,
 L
ou
is
ia
na
, M
ai
ne
, M
as
sa
ch
us
et
ts
, M
ic
hi
ga
n,
 
M
in
ne
so
ta
, M
is
so
ur
i, 
M
on
ta
na
, N
eb
ra
sk
a,
 N
ev
ad
a,
 N
ew
 H
am
ps
hi
re
, N
ew
 J
er
se
y,
 N
ew
 M
ex
ic
o,
 N
ew
 Y
or
k,
 N
or
th
 D
ak
ot
a,
 O
kl
ah
om
a,
 O
re
go
n,
 P
en
ns
yl
va
ni
a,
 R
ho
de
 Is
la
nd
, S
ou
th
 C
ar
ol
in
a,
 S
ou
th
 D
ak
ot
a,
 T
ex
as
, 
U
ta
h,
 W
as
hi
ng
to
n,
 W
es
t 
V
irg
in
ia
, W
yo
m
in
g.
 T
he
se
 r
eg
is
tr
ie
s 
co
ve
r 
ab
ou
t 
80
%
 o
f 
th
e 
U
S
 p
op
ul
at
io
n.
  
   ||   
 A
P
C
 is
 b
as
ed
 o
n 
ra
te
s 
th
at
 w
er
e 
ag
e 
st
an
da
rd
iz
ed
 t
o 
th
e 
20
00
 U
S
 s
ta
nd
ar
d 
po
pu
la
tio
n.
 1
99
6 –
 20
05
 A
P
C
s 
fo
r 
al
l r
ac
es
 a
nd
 e
th
ni
ci
tie
s,
 w
hi
te
, b
la
ck
, A
P
I, 
an
d 
H
is
pa
ni
c 
(2
8 
st
at
es
 a
nd
 M
et
ro
po
lit
an
 A
tla
nt
a)
: A
la
sk
a,
 
C
al
ifo
rn
ia
, C
ol
or
ad
o,
 C
on
ne
ct
ic
ut
, D
el
aw
ar
e,
 F
lo
rid
a,
 M
et
ro
po
lit
an
 A
tla
nt
a,
 H
aw
ai
i, 
Id
ah
o,
 Il
lin
oi
s,
 Io
w
a,
 K
en
tu
ck
y,
 L
ou
is
ia
na
, M
ai
ne
, M
ic
hi
ga
n,
 M
in
ne
so
ta
, M
on
ta
na
, N
eb
ra
sk
a,
 N
ew
 J
er
se
y,
 N
ew
 M
ex
ic
o,
 
N
ew
 Y
or
k,
 O
re
go
n,
 P
en
ns
yl
va
ni
a,
 R
ho
de
 Is
la
nd
, T
ex
as
, U
ta
h,
 W
as
hi
ng
to
n,
 W
es
t 
V
irg
in
ia
, W
yo
m
in
g.
 T
he
se
 r
eg
is
tr
ie
s 
co
ve
r 
ab
ou
t 
65
%
 o
f 
th
e 
U
S
 p
op
ul
at
io
n.
  
  ¶
  
 Fo
r 
al
l s
ite
s,
 m
ye
lo
dy
sp
la
st
ic
 s
yn
dr
om
es
 a
re
 in
cl
ud
ed
 f
or
 t
he
 r
at
e 
ca
lc
ul
at
io
ns
 b
ut
 n
ot
 f
or
 t
he
 A
P
C
 c
al
cu
la
tio
ns
; t
he
y 
ar
e 
ex
cl
ud
ed
 f
ro
m
 c
an
ce
r-
sp
ec
ifi
c 
an
al
ys
is
. O
va
ry
 e
xc
lu
de
s 
bo
rd
er
lin
e 
tu
m
or
s.
  
   #   
 A
P
C
 is
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
tly
 d
iff
er
en
t 
fr
om
 z
er
o 
(t
w
o-
si
de
d 
 P
  <
 .0
5,
 c
al
cu
la
te
d 
us
in
g 
a 
 t  
te
st
).   
T
ab
le
 3
 (
co
n
ti
n
u
ed
).
1680   Special Article | JNCI Vol. 100, Issue 23  |  December 3, 2008
 T
ab
le
 4
  .    D
ea
th
 r
at
es
 f
o
r 
20
01
 – 2
00
5 
an
d
 s
h
o
rt
-t
er
m
 t
re
n
d
s 
fo
r 
19
96
 – 2
00
5 
fo
r 
th
e 
to
p
 1
5 
ca
n
ce
rs
 b
y 
se
x,
 r
ac
e,
 a
n
d
 e
th
n
ic
it
y 
in
 t
h
e 
U
n
it
ed
 S
ta
te
s *
   
  S
ex
/c
an
ce
r 
si
te
 o
r 
ty
p
e  †
  
A
ll 
ra
ce
s/
et
h
n
ic
it
ie
s
W
h
it
e  ‡
  
B
la
ck
  ‡  
A
P
I  ‡
    
A
I/
A
N
 (
C
H
S
D
A
 c
o
u
n
ti
es
)  ‡
  
H
is
p
an
ic
  ‡  ,
 §  
 R
an
k
R
at
e  |
|  
A
P
C
 ¶ 
R
an
k
R
at
e  |
|  
A
P
C
 ¶ 
R
an
k
R
at
e  |
|  
A
P
C
 ¶ 
R
an
k
R
at
e  |
|  
A
P
C
 ¶ 
R
an
k
R
at
e  |
|  
A
P
C
 ¶ 
R
an
k
R
at
e  |
|  
A
P
C
 ¶   
  M
al
es
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 A
ll 
si
te
s
 
23
4.
4
 – 1
.7
  #  
 
23
0.
7
 – 1
.5
  #  
 
31
3.
1
 – 2
.5
  #  
 
13
8.
8
 – 2
.0
  #  
 
19
0.
0
 – 0
.7
 
15
9.
1
 – 1
.9
  #   
    
 Lu
ng
 a
nd
 b
ro
nc
hu
s
1
72
.0
 – 2
.0
  #  
1
71
.3
 – 1
.8
  #  
1
93
.1
 – 2
.8
  #  
1
37
.5
 – 1
.6
  #  
1
50
.2
 – 2
.3
  #  
1
35
.0
 – 2
.5
  #   
    
 P
ro
st
at
e
2
26
.7
 – 4
.1
  #  
2
24
.6
 – 4
.0
  #  
2
59
.4
 – 4
.0
  #  
4
11
.0
 – 4
.1
  #  
2
21
.1
 – 1
.9
2
20
.6
 – 3
.5
  #   
    
 C
ol
on
 a
nd
 r
ec
tu
m
3
22
.7
 – 2
.6
  #  
3
22
.1
 – 2
.7
  #  
3
31
.8
 – 1
.6
  #  
3
14
.4
 – 2
.1
  #  
3
20
.5
 – 1
.0
3
16
.5
 – 2
.0
  #   
    
 P
an
cr
ea
s
4
12
.2
0.
1
4
12
.1
0.
2  #
  
4
15
.4
 – 0
.9
  #  
6
8.
0
 – 0
.4
7
8.
6
3.
3
5
9.
2
0.
3 
    
 Le
uk
em
ia
5
9.
9
 – 0
.8
  #  
5
10
.2
 – 0
.7
  #  
8
8.
5
 – 1
.8
  #  
8
5.
1
 – 0
.6
10
5.
7
1.
0
8
6.
3
 – 1
.1
 
    
 N
on
-H
od
gk
in
 ly
m
ph
om
a
6
9.
3
 – 2
.7
  #  
6
9.
7
 – 2
.6
  #  
11
6.
4
 – 3
.7
  #  
7
5.
6
 – 3
.7
  #  
9
5.
8
 – 2
.1
7
6.
7
 – 4
.3
  #   
    
 E
so
ph
ag
us
7
7.
8
0.
5  #
  
8
7.
8
1.
3  #
  
7
9.
8
 – 4
.6
  #  
10
3.
1
 – 3
.5
8
7.
1
5.
3  #
  
10
4.
2
 – 2
.1
  #   
    
 U
rin
ar
y 
bl
ad
de
r
8
7.
5
 – 0
.3
  #  
7
7.
9
 – 0
.2
13
5.
4
 – 1
.0
11
2.
9
0.
0
13
2.
9
 **
 
11
4.
0
 – 1
.0
 
    
 Li
ve
r 
an
d 
in
tr
ah
ep
at
ic
 b
ile
 d
uc
t
9
7.
3
2.
1  #
  
9
6.
7
2.
1  #
  
6
10
.3
2.
5  #
  
2
15
.2
 – 1
.3
  #  
4
10
.6
1.
4
4
11
.1
1.
5  #
   
    
 K
id
ne
y 
an
d 
re
na
l p
el
vi
s
10
6.
0
 – 0
.4
10
6.
2
 – 0
.3
12
6.
1
 – 0
.5
13
2.
4
 – 4
.0
  #  
6
9.
3
0.
2
9
5.
3
0.
5 
    
 S
to
m
ac
h
11
5.
7
 – 3
.7
  #  
12
5.
0
 – 3
.8
  #  
5
11
.5
 – 3
.8
  #  
5
10
.1
 – 3
.9
  #  
5
9.
9
0.
1
6
8.
7
 – 2
.6
  #   
    
 B
ra
in
 a
nd
 o
th
er
 n
er
vo
us
 s
ys
te
m
12
5.
4
 – 1
.0
  #  
11
5.
7
 – 1
.0
  #  
15
3.
2
 – 0
.4
12
2.
6
2.
2
14
2.
8
3.
1
13
3.
4
 – 0
.5
 
    
 M
ye
lo
m
a
13
4.
6
 – 1
.1
  #  
14
4.
3
 – 0
.9
  #  
9
8.
3
 – 2
.0
  #  
14
1.
9
 – 2
.9
  #  
11
4.
6
1.
8
12
3.
6
 – 1
.8
 
    
 O
ra
l c
av
ity
 a
nd
 p
ha
ry
nx
14
4.
0
 – 1
.9
  #  
15
3.
8
 – 1
.7
  #  
10
6.
7
 – 3
.0
  #  
9
3.
3
 – 3
.0
  #  
12
3.
8
 **
 
14
2.
6
 – 4
.0
  #   
    
 M
el
an
om
a 
of
 t
he
 s
ki
n
15
3.
9
 – 0
.2
13
4.
4
 – 0
.1
24
0.
5
 – 0
.4
19
0.
5
 **
 
16
1.
5
 **
 
17
0.
9
 – 3
.8
  #   
    
 La
ry
nx
16
2.
3
 – 2
.3
  #  
16
2.
1
 – 2
.0
  #  
14
4.
8
 – 3
.3
  #  
16
0.
8
 – 3
.3
15
2.
1
 **
 
15
1.
9
 – 4
.1
  #   
    
 S
of
t 
tis
su
e 
in
cl
ud
in
g 
he
ar
t  
 
17
1.
4
 – 2
.1
  #  
18
1.
4
 – 1
.9
  #  
16
1.
5
 – 3
.1
  #  
15
0.
9
 – 2
.5
18
1.
1
 **
 
16
1.
0
 – 3
.2
  #   
 Fe
m
al
es
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 A
ll 
si
te
s
 
15
9.
9
 – 1
.0
  #  
 
15
9.
2
 – 0
.9
  #  
 
18
6.
8
 – 1
.2
  #  
 
95
.9
 – 1
.1
  #  
 
14
2.
0
 – 0
.2
 
10
5.
3
 – 1
.1
  #   
    
 Lu
ng
 a
nd
 b
ro
nc
hu
s
1
41
.0
0.
1
1
42
.0
0.
2
1
39
.9
0.
1
1
18
.5
 – 0
.7
1
33
.8
2.
9  #
  
2
14
.6
 – 0
.5
 
    
 B
re
as
t
2
25
.0
 – 2
.1
  #  
2
24
.4
 – 2
.2
  #  
2
33
.5
 – 1
.5
  #  
2
12
.6
0.
0
2
17
.1
1.
0
1
15
.8
 – 2
.5
  #   
    
 C
ol
on
 a
nd
 r
ec
tu
m
3
15
.9
 – 2
.5
  #  
3
15
.3
 – 2
.6
  #  
3
22
.4
 – 1
.9
  #  
3
10
.2
 – 2
.1
  #  
3
14
.2
 – 2
.2
3
10
.9
 – 0
.9
 
    
 P
an
cr
ea
s
4
9.
3
0.
2  #
  
5
9.
0
0.
4  #
  
4
12
.4
 – 0
.7
  #  
4
6.
9
0.
5
5
7.
2
 – 1
.3
4
7.
6
0.
7 
    
 O
va
ry
5
8.
8
 – 0
.1
4
9.
2
 – 0
.1
5
7.
5
 – 0
.1
7
4.
9
0.
7
4
7.
5
0.
6
5
6.
0
0.
4 
    
 N
on
-H
od
gk
in
 ly
m
ph
om
a
6
5.
9
 – 3
.2
  #  
6
6.
2
 – 3
.3
  #  
11
4.
2
 – 2
.3
  #  
8
3.
8
 – 1
.4
8
4.
9
0.
5
8
4.
6
 – 2
.8
  #   
    
 Le
uk
em
ia
7
5.
6
 – 1
.1
  #  
7
5.
7
 – 1
.0
  #  
9
5.
2
 – 1
.3
  #  
9
3.
0
 – 2
.1
  #  
10
4.
1
 **
 
9
4.
0
 – 1
.5
  #   
    
 U
te
rin
e 
co
rp
us
 a
nd
 u
te
ru
s 
N
O
S
8
4.
1
0.
1
8
3.
9
0.
1
6
7.
1
0.
3
10
2.
4
0.
4
13
3.
1
 **
 
11
3.
2
0.
0 
    
 B
ra
in
 a
nd
 o
th
er
 n
er
vo
us
 s
ys
te
m
9
3.
6
 – 1
.3
  #  
9
3.
9
 – 1
.1
  #  
16
2.
1
 – 1
.8
  #  
12
1.
5
 – 0
.1
16
1.
4
 **
 
14
2.
4
0.
1 
    
 Li
ve
r 
an
d 
in
tr
ah
ep
at
ic
 b
ile
 d
uc
t
10
3.
1
1.
1  #
  
10
2.
9
1.
0  #
  
12
3.
9
0.
6
5
6.
6
0.
5
6
6.
6
3.
2
6
5.
1
1.
6  #
   
    
 M
ye
lo
m
a
11
3.
0
 – 1
.2
  #  
12
2.
8
 – 1
.1
  #  
7
6.
0
 – 1
.7
  #  
13
1.
4
 – 1
.9
12
3.
6
 – 3
.7
12
2.
6
 – 1
.7
 
    
 S
to
m
ac
h
12
2.
9
 – 2
.7
  #  
13
2.
5
 – 2
.8
  #  
8
5.
5
 – 3
.3
  #  
6
5.
9
 – 4
.4
  #  
7
5.
2
 – 3
.5
7
5.
0
 – 2
.0
  #   
    
 K
id
ne
y 
an
d 
re
na
l p
el
vi
s
13
2.
7
 – 0
.5
  #  
11
2.
8
 – 0
.4
15
2.
7
 – 0
.6
15
1.
2
 – 1
.2
9
4.
3
 – 0
.8
13
2.
4
0.
8 
    
 U
te
rin
e 
ce
rv
ix
14
2.
5
 – 3
.4
  #  
14
2.
3
 – 3
.2
  #  
10
4.
7
 – 4
.3
  #  
11
2.
2
 – 5
.2
  #  
11
3.
7
 – 2
.8
10
3.
2
 – 3
.1
  #   
    
 U
rin
ar
y 
bl
ad
de
r
15
2.
3
 – 0
.8
  #  
15
2.
2
 – 0
.6
  #  
14
2.
8
 – 1
.7
  #  
16
1.
0
 – 0
.4
18
1.
2
 **
 
15
1.
4
0.
4 
    
 E
so
ph
ag
us
17
1.
7
 – 0
.9
  #  
17
1.
6
 – 0
.2
13
2.
8
 – 3
.9
  #  
18
0.
8
 – 2
.0
15
1.
6
 **
 
17
0.
9
 – 3
.5
  #   
    
 O
ra
l c
av
ity
 a
nd
 p
ha
ry
nx
18
1.
5
 – 2
.4
  #  
18
1.
5
 – 2
.2
  #  
17
1.
6
 – 4
.5
  #  
14
1.
4
 – 0
.5
17
1.
3
 **
 
19
0.
8
 – 1
.9
 
    
 G
al
lb
la
dd
er
20
0.
8
 – 2
.5
  #  
20
0.
8
 – 2
.6
  #  
19
1.
0
 – 1
.6
17
0.
8
 – 3
.5
14
2.
2
 **
 
16
1.
3
 – 5
.4
  #    
  *  
 A
P
I   =
   A
si
an
/P
ac
ifi
c 
Is
la
nd
er
; A
I/A
N
   =
   A
m
er
ic
an
 In
di
an
/A
la
sk
a 
N
at
iv
e;
 IH
S
   =
   In
di
an
 H
ea
lth
 S
er
vi
ce
; C
H
S
D
A
   =
   IH
S
 C
on
tr
ac
t 
H
ea
lth
 S
er
vi
ce
 D
el
iv
er
y 
A
re
a;
 A
P
C
   =
   a
nn
ua
l p
er
ce
nt
 c
ha
ng
e;
 N
O
S
   =
   n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
. 
S
ou
rc
e:
 N
at
io
na
l C
en
te
r 
fo
r 
H
ea
lth
 S
ta
tis
tic
s,
 2
00
5 
M
or
ta
lit
y 
S
pe
ci
al
 R
es
ea
rc
h 
Fi
le
.  
   †   
 C
an
ce
rs
 a
re
 s
or
te
d 
in
 d
es
ce
nd
in
g 
or
de
r a
cc
or
di
ng
 to
 s
ex
-s
pe
ci
fic
 ra
te
s 
fo
r a
ll 
ra
ce
s 
an
d 
et
hn
ic
iti
es
. M
or
e 
th
an
 1
5 
ca
nc
er
s 
m
ay
 a
pp
ea
r u
nd
er
 m
al
es
 a
nd
 fe
m
al
es
 to
 in
cl
ud
e 
th
e 
to
p 
15
 c
an
ce
rs
 in
 e
ve
ry
 ra
ce
 a
nd
 e
th
ni
ci
ty
 g
ro
up
.  
   ‡   
 W
hi
te
, b
la
ck
, A
P
I, 
an
d 
A
I/A
N
 (C
H
S
D
A
 c
ou
nt
ie
s)
 p
op
ul
at
io
ns
 in
cl
ud
e 
H
is
pa
ni
c 
an
d 
no
n-
H
is
pa
ni
c;
 t
he
 r
ac
e 
an
d 
et
hn
ic
ity
 c
at
eg
or
ie
s 
ar
e 
no
t 
m
ut
ua
lly
 e
xc
lu
si
ve
.  
  §  
 D
at
a 
fo
r 
H
is
pa
ni
c 
ex
cl
ud
e 
M
ai
ne
, M
in
ne
so
ta
, N
ew
 H
am
ps
hi
re
, N
or
th
 D
ak
ot
a,
 a
nd
 O
kl
ah
om
a.
  
   ||   
 R
at
es
 (p
er
 1
00
   0
00
 p
er
so
ns
) w
er
e 
ag
e 
st
an
da
rd
iz
ed
 t
o 
th
e 
20
00
 U
S
 s
ta
nd
ar
d 
po
pu
la
tio
n.
  
  ¶
  
 A
P
C
 is
 b
as
ed
 o
n 
ra
te
s 
th
at
 w
er
e 
ag
e 
st
an
da
rd
iz
ed
 t
o 
th
e 
20
00
 U
S
 s
ta
nd
ar
d 
po
pu
la
tio
n.
  
   #   
 A
P
C
 is
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
tly
 d
iff
er
en
t 
fr
om
 z
er
o 
(t
w
o-
si
de
d 
 P
  <
 .0
5,
 c
al
cu
la
te
d 
us
in
g 
a 
 t  
te
st
).  
  **
   S
ta
tis
tic
 c
ou
ld
 n
ot
 b
e 
ca
lc
ul
at
ed
. T
he
 a
nn
ua
l p
er
ce
nt
 c
ha
ng
e 
is
 b
as
ed
 o
n 
fe
w
er
 t
ha
n 
10
 c
an
ce
r 
ca
se
s 
fo
r 
at
 le
as
t 
1 
y 
w
ith
in
 t
he
 t
im
e 
in
te
rv
al
.   
jnci.oxfordjournals.org   JNCI |  Special Article 1681
1975 through 2005 ( Figure 1 ). Data from the SEER-9 areas are 
shown separately to illustrate that lung cancer incidence rates in 
these registries are substantially lower than US incidence 
rates, especially in men. Furthermore, the lung cancer mortality 
rates reached a plateau earlier in the SEER-9 registries than 
nationally in both men and women, especially in men. In the 
SEER-9 registries, the trends in lung cancer incidence are remark-
ably similar to those for mortality. 
 Temporal trends in age-specifi c lung cancer incidence rates 
beginning at ages 30 – 34 in SEER areas are shown by sex ( Figure 2 ). 
Among men, incidence rates generally decreased in all age 
groups since 1990, with the decrease beginning earlier at 
younger ages. In contrast, among women the incidence rates 
continued to increase in the three oldest age groups ( 75 – 79 , 
 80 – 84 ,  ≥ 85 years), and the decreases at younger ages were 
smaller and less constant compared with those in men aged 50 – 69 
years. The seemingly erratic patterns in the rates for women 
between ages 30 and 49 years refl ect birth cohort patterns of smok-
ing initiation as discussed below. The age-specifi c mortality pat-
terns ( Figure 3 ) are generally similar to the incidence patterns but 
show the rise in lung cancer death rates over a broader period, from 
1950 through 1975. 
 Age-specifi c lung cancer death rates have been decreasing in all 
age groups among men born after 1925 ( Figure 4 ). Among women, 
the death rates have not yet leveled off in the oldest age groups (75 
years and older), and the decrease below age 50 years has been 
interrupted among those born between 1950 and 1960. The rela-
tionship of this interruption to patterns of smoking initiation 
among women who passed through adolescence during the late 
1960s and 1970s is discussed below. 
 State-specifi c lung cancer incidence and mortality rates and 
trends for all racial and ethnic groups combined are shown in 
 Table 5 . Incidence rates (per 100 000) for 2001 – 2005 ranged from 
39.6 in Utah to 136.2 in Kentucky among men and from 22.4 in 
Utah to 76.2 in Kentucky among women. Lung cancer incidence 
rates in men decreased from 1996 through 2005 in all but four 
(Nebraska, Hawaii, Idaho, and Utah) of the 28 states in which 
incidence trends could be measured. In contrast, lung cancer inci-
dence rate in women decreased over this time in only one state 
(California) and increased in eight states (Pennsylvania, Illinois, 
Iowa, Michigan, Minnesota, Nebraska, Kentucky, and Idaho). 
 Similar to the incidence rates, mortality rates (per 100 000) for 
2001 – 2005 ranged from 33.7 in Utah to 111.5 in Kentucky for men 
and from 16.9 in Utah to 55.9 in Kentucky for women ( Table 5 ). 
Among men, the lung cancer death rate decreased during the years 
1996 – 2005 in 43 of the 50 states and in the District of Columbia, 
whereas in women, the death rate decreased in only three states 
(California, New Jersey, and Texas) and increased in 13 states 
(Alabama, Arkansas, Kentucky, Louisiana, Mississippi, North 
Carolina, South Carolina, Tennessee, Kansas, South Dakota, 
Indiana, Michigan, and Iowa). Further analyses examined these 
mortality trends separately in non-Hispanic whites and blacks 
( Supplementary Table 1 , available online). Only in California and 
in the District of Columbia did the death rates decrease from 1996 
through 2005 among non-Hispanic white women. 
 The long-term (1975 – 2005) trends in lung cancer death rates 
for all races and ethnicities combined for three states represent-
ing the highest (Kentucky) or lowest (Utah) rates or greatest 
changes (California), as well as the US average, are shown in 
 Figure 5 . Among men, the decrease in the lung cancer death rate 
began fi rst and has been largest in California, where the male 
death rate is approaching that in Utah. The death rate among 
men has also decreased since the early 1990s in Kentucky, 
although the trend from 1996 through 2005 was not statistically 
signifi cant ( Table 5 ). However, for women, the lung cancer death 
rate continued to rise in Kentucky, while it decreased statistically 
signifi cantly in California. The death rates in Utah were consis-
tently low. 
 Figure 1 .  Trends in age-standardized lung can-
cer incidence and death rates by sex, United 
States, 1975 – 2005.  Solid lines represent fi tted 
values based on joinpoint analyses.  Squares 
represent observed rates. SEER-9 incidence 
data for 1975 – 2005 are from the Surveillance, 
Epidemiology, and Ends Results (SEER)-9 areas 
and or cover 10% of the US population. US inci-
dence data from 1996 to 2005 are from 29 SEER 
and or National Program of Cancer Registries 
areas reported by the North American 
Association of Central Cancer Registries as 
meeting high-quality data standards and cover 
about 65% of the US population. SEER-9 inci-
dence data are adjusted for delays in reporting, 
but US incidence data are not. US and SEER-9 
mortality data for 1975 – 2005 are from the 
National Center for Health Statistics, 2005 
Mortality Special Research File. 
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 Figure 2 .  Trends in age-specifi c lung cancer incidence 
rates by year of diagnosis and sex, United States, 
1975 – 2005. Data are from Surveillance, Epidemiology, 
and Ends Results (SEER)-9 areas, and data points are 
based on 2-y average rates with the exception of the 
last point, which averages 3-y rates (1975 – 1976, 1977 –
 1978,  … , 2001 – 2002, 2003 – 2005). The SEER-9 areas 
cover about 10% of the US population. 
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 A wide variation in adult and youth smoking prevalence and in 
indices of tobacco control was observed among the 50 states and 
the District of Columbia ( Table 6 ). Similar to the lung cancer inci-
dence and death rates, current smoking prevalence in adults (18 
years and older) in 2006 was lowest in Utah and highest in 
Kentucky in both men and women. The prevalence of current 
smoking in Utah and Kentucky was 10.4% (95% confi dence inter-
val [CI]  =  8.7% to 12.3%) and 29.1% (95% CI  =  26.2% to 32.1%), 
respectively, in men and 9.3% (95% CI  =  7.9% to 10.8%) and 
28.0% (95% CI  =  26.0% to 30.1%), respectively, in women. From 
1997 through 2006, adult smoking prevalence decreased in 29 
states in men and 30 states in women. States with the largest annual 
decrease in both sexes include Connecticut, California, Nevada, 
Utah, and Washington. Smoking prevalence remained stable in the 
remaining 21 states in men and 20 states in women, except in 
Mississippi where it increased at the rate of 1.0% per year among 
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 Figure 3 .  Trends in age-specifi c lung 
cancer death rates by year of death and 
sex, United States, 1950 – 2005. Rates 
include cancers of the lung, bronchus, 
pleura, and trachea. Data are from the 
National Center for Health Statistics, 
2005 Mortality Special Research File. 
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women. Corresponding state-specifi c smoking data for non- 
Hispanic whites are shown in  Supplementary Table 2 (available 
online). The prevalence of cigarette use in the last month among 
youth aged 12 – 17 years in 2004 – 2005 ranged from 7.1% (95% 
CI  =  5.7% to 8.9%) in the District of Columbia to 17.2% (95% 
CI  =  14.6% to 20.1%) in Kentucky ( Table 6 ). 
 The tobacco tax is generally lower in many Southern and/
or tobacco-growing states (North Carolina, Kentucky, Tennessee, 
South Carolina, Virginia, West Virginia, Florida, Georgia, 
Alabama, Mississippi, and Louisiana) than in other regions ( Table 
6 ). Only three states (Delaware, Colorado, and Maine) meet the 
CDC’s minimum spending for comprehensive tobacco preven-
tion programs for 2008 based on projected state budgets for 2008. 
Thirty states and the District of Columbia failed to meet at least 
50% of the CDC’s minimum spending for tobacco control pre-
vention in 2008. 
 Trends in initiation of smoking among 12- to 17-year-old ado-
lescents in the United States, 1940 – 2000, show that initiation rates 
increased sharply in girls from 1965 through 1975 ( Figure 6 ). 
Subsequently, rates decreased through the mid-1980s in both girls 
and boys but rose again from 1990 through the mid-1990s, espe-
cially in boys. Initiation rates were similar for boys and girls during 
the most recent data years (1996 – 2000). 
 Discussion 
 This is the first Annual Report to the Nation to document a 
decline in both the incidence and the death rates from all cancers 
combined in both men and women. These declines occurred in 
most racial and ethnic groups and partly reflect decreases in the 
three most common cancers in men (lung, colorectum, and pros-
tate) and two of the three most common cancers in women (breast 
and colorectum), as well as the leveling off of lung cancer death 
rates in women. These cancers account for about half of all cancer 
cases and deaths in both men and women. The sustained declines 
in cancer death rates overall and for the three major cancer sites in 
men and two major cancer sites in women have been discussed 
previously ( 2 – 10 ). Declines in cancer death rates indicate real 
progress in cancer control, reflecting a combination of primary 
prevention, early detection, and treatment. 
 Trends in incidence are more diffi cult to interpret, because 
both increasing and decreasing trends can result from changes in 
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 Figure 4 .  Trends in age-specifi c lung cancer 
death rates by year of birth and sex, United 
States, 1865 – 1970. Rates include cancers of 
the lung, bronchus, pleura, and trachea. 
The points vertically above each cohort 
year portray the cohort’s age-specifi c mor-
tality experience. Data are from the National 
Center for Health Statistics, 2005 Mortality 
Special Research File. 
screening and diagnostic practices as well as changes in exposure to 
risk factors. Incidence declines attributed to reductions in risk fac-
tors include the decrease in lung cancer in men caused by historical 
patterns of smoking cessation ( 32 , 33 ) and sharp declines in breast 
cancer incidence in 2002 – 2003 following reduced use of hormonal 
replacement therapy (HRT) ( 34 – 37 ). The decline in breast cancer 
incidence attributed to HRT use is particularly notable because of 
the short lag time between changes in exposure and resulting 
changes in incidence. A similarly rapid change in a hormonally 
related cancer following changes in hormonal therapy was seen in 
the 1970s when the incidence of endometrial cancer fi rst increased 
and then decreased with the rise and fall of HRT formulations 
containing estrogen ( 38 , 39 ). 
 Changes in incidence rates can also be related to changes in 
use of diagnostic and screening modalities. The accelerated 
decline in the colorectal cancer incidence rate since 1998 may be 
associated with increased use of colorectal cancer screening, 
which prevents cancer through removal of precancerous adenom-
atous polyps ( 7 , 10 , 40 , 41 ). Between 2000 and 2005, the percent-
age of adults aged 50 years and older who reported having had 
colonoscopy increased from 20% to 39%, whereas the percent-
age reporting testing for fecal occult blood decreased from 17% 
to 12% ( 42 ). Overall, the use of colorectal screening among 
adults 50 years and older increased from 27% in 1987 to 50% in 
2005 ( 42 , 43 ). 
 Changes in use of mammography may have also contributed to 
recent declines in breast cancer incidence trends that began in 
1999. The prevalence of recent mammography began to stabilize 
or decline in the late 1990s after increasing for many years ( 44 ); 
this trend may have contributed to the decline in incidence, due to 
decreased detection or reduced number of undiagnosed prevalent 
cancers ( 35 , 45 ). Long-term declines in cervical cancer incidence in 
women are likely related to widespread dissemination of cervical 
cancer screening ( 46 – 48 ). 
 In contrast to mammography and colorectal cancer screening, 
the benefi ts of prostate-specifi c antigen (PSA) screening in reduc-
ing morbidity and mortality from prostate cancer have not yet 
been established ( 49 ). Trends in use of PSA screening have 
undoubtedly infl uenced prostate cancer incidence trends over the 
last several decades ( 50 ), and the leveling off of PSA screening may 
be contributing to the recent decline in prostate cancer incidence 
because of decreased detection, or reduced number of undiagnosed 
prevalent cancers. According to the National Ambulatory Medical 
Survey ( 51 ), the frequency of PSA testing during visits for a 
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general medical examination among American men increased 
from 1995 through 2002 and then leveled off through 2004. 
 The increasing incidence of several other cancers is related, at 
least in part, to increased detection and use of diagnostic and imag-
ining technology. These cancers include melanoma of the skin, 
cancer of the kidney and renal pelvis, and thyroid cancer ( 52 – 56 ). 
 With respect to trends in lung cancer, tobacco use, and 
tobacco control, this report documents large geographic varia-
tion in tobacco smoking that, together with generational differ-
ences in past smoking behavior, is delaying the decrease in lung 
cancer death rates in women and slowing the decrease in men. 
Cigarette smoking alone still accounts for approximately 30% of 
all cancer deaths in the United States, despite reductions in smok-
ing prevalence ( 57 ). Most (80%) of these smoking-attributable 
cancer deaths involve lung cancer, although smoking also causes 
cancers of the oral cavity, pharynx, larynx, esophagus, stomach, 
bladder, pancreas, liver, kidney, uterine cervix, and myeloid leuke-
mia ( 58 ). Lung cancer is commonly perceived by public health 
professionals as the sentinel health consequence of cigarette smok-
ing because although smoking causes more deaths from cardiovas-
cular and respiratory diseases than from lung cancer ( 58 ), those 
conditions are less strongly associated with smoking than is lung 
cancer. 
 Sex differences in lung cancer incidence and death rates, and 
particularly the delayed increase and then leveling off of lung can-
cer risk in women compared with men ( Figure 1 ), have been 
described repeatedly elsewhere ( 32 , 33 , 59 ). These temporal differ-
ences refl ect the later uptake of cigarette smoking among women, 
who began smoking predominantly during and after World War 
II, compared with men, who began cigarette smoking in the early 
20th century, with large peaks of initiation during the two World 
Wars ( 60 , 61 ). Because of the historical differences in smoking pat-
terns, the sustained decrease in lung cancer incidence and death 
rates in men has been a major contributor to the overall decrease 
in male cancer incidence and death rates ( 62 ), whereas the leveling 
off of the lung cancer death rate among women has only recently 
facilitated the downturn in the overall female cancer death rate. 
 Less attention has been paid to the prominent state and regional 
variations in the trends in lung cancer and tobacco use in men and 
women, particularly as these relate to various indices of state 
tobacco control activity. Although the lung cancer death rate 
among men has been decreasing nationally since the early 1990s, 
the rate of this decrease varies substantially by state and geographic 
region. For example, the average percentage decrease in the lung 
cancer death rate among men in California from 1996 through 
2005 (2.8% per year) is more than twice that of many states in the 
Midwest and South. The geographic variation is even more extreme 
among women, for whom the lung cancer death rate increased from 
1996 through 2005 in 13 states and decreased in only three. 
Although fewer data on trends at the state level are available for 
lung cancer incidence than for mortality, in fi ve states (Pennsylvania, 
Illinois, Minnesota, Nebraska, and Idaho), lung cancer incidence 
among women was increasing and mortality rates were stable dur-
ing the same time interval. Our fi ndings help to explain why the 
lung cancer incidence and death rates among women nationally 
have not decreased, despite reductions in smoking prevalence. 
At least three factors contribute to the rates and trends among 
women ( Tables 1 – 4 ). First, age-specifi c incidence and death rates 
continue to increase for age groups 70 and above ( Figures 2 and  3 ), 
and rates occurring in these age groups heavily infl uence the trend 
in the age-standardized rates because they contribute to more than 
50% of the age-standardized rates. Second, smoking cessation rates 
are historically lower in women than men, especially at older ages 
( 63 ). Based on data from the National Health Interview Surveys, 
the “quit ratio,” or fraction of ever smokers who had stopped smok-
ing, was more than 50% higher in men than women aged 65 years 
and older in 1965 and 1970, and remained 15% – 19% higher in 
1990 and 1994 ( 63 ). 
 A third factor that is delaying a decrease in female lung cancer 
incidence and death rates nationally is that incidence and death 
 Figure 5 .  Trends in age-standardized lung 
cancer death rate for the US and selected 
states by sex, 1975 – 2005.  Solid lines represent 
fi tted values based on joinpoint analyses. 
 Squares represent observed rates. Data are 
from the National Center for Health Statistics, 
2005 Mortality Special Research File. 
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rates continue to increase in certain regions of the United States. 
All of the 13 states in which the lung cancer death rates increased 
in women from 1996 through 2005 are located in the South and 
Midwest, where, on average, the prevalence of smoking is higher 
and the annual percentage decrease in current smoking among 
adult women is lower than in the West and Northeast. State 
variations in smoking prevalence are infl uenced by several factors, 
which include public awareness about the harmful health effects 
of tobacco use, social norms about tobacco use, educational levels 
within the state, racial and ethnic variations among the states, 
tobacco control activities at the state and local level ( 64 , 65 ), and 
industry promotional activities ( 66 – 69 ). California was the fi rst 
state in the United States to implement a comprehensive state-
wide tobacco control program ( 70 ) and has made the greatest 
progress in reducing tobacco use ( 71 – 74 ), although Utah contin-
ues to have the lowest smoking prevalence. Adult smoking preva-
lence among women in California decreased from 14.5% in 1997 
to 11.4% in 2006 ( Table 6 ). Many states in the South and 
Midwest have only recently achieved a reduction in female smok-
ing prevalence and have not yet experienced a leveling off or 
decrease of lung cancer incidence and death rates among women. 
For example, the percentage of adult female current smokers 
in Kentucky changed little from 1997 (28.7%) to 2006 (28%) 
( Table 6 ). 
 Most Southern and Midwestern states continue to have a 
high prevalence of smoking and low excise tax ( Table 6 ), despite 
compelling evidence that excise taxes and other components of 
comprehensive tobacco control can achieve substantial reduc-
tions in tobacco use ( 75 , 76 ). Many Southern states have histori-
cally been economically dependent on tobacco farming 
and production ( 77 ). The exceptionally low lung cancer rate in 
Utah refl ects the religious prohibition against smoking among 
Mormons ( 78 , 79 ). 
 Nationally, the anticipated future decline in age-standardized 
lung cancer rates in women will be offset by the generation of 
women born between 1950 and 1960 who passed through adoles-
cence and young adulthood at the time when cigarette brands such 
as Virginia Slims were introduced and marketed intensively to 
women ( 26 , 33 , 80 , 81 ). A sharp increase in smoking initiation 
occurred among these women between 1965 and 1975 ( Figure 6 ). 
These same birth cohorts account for the interruption in the 
decline in female lung cancer incidence and death rates between 
ages 30 and 49 years ( Figures 2 – 4 ). Women who were born in 
this era will likely continue to offset future decreases in lung 
cancer incidence and death rates in other birth cohorts over the 
next 50 years. 
 As mentioned above, tobacco smoking causes many cancers in 
addition to lung cancer. However, only three of these cancers 
(cancers of the oral cavity, esophagus, and larynx) have a smoking-
attributable mortality of greater than 50% ( 57 ). Incidence and 
death rates for cancer of the oral cavity and larynx and incidence 
rates for squamous cell carcinoma of the esophagus (the histo-
logical type most strongly associated with smoking) have 
decreased in both men and women over the past 15 years (data 
not shown), following reduction of smoking prevalence over the 
past 40 years. 
 Limitations 
 Surveillance of cancer in the United States now covers the majority 
of the population for incidence and the entire population for mor-
tality. However, certain limitations in data sources, data collection, 
and analyses may have influenced the findings of this report. First, 
national and state population estimates provided by the Census 
Bureau for the period 2000 through 2005 (2006 vintage) were 
developed based on new methodology that is considered more 
demographically plausible and more accurate (L. Sink, MS, Bureau 
of Census, personal communication). The change in methodology 
had little effect on the national population estimates but had a 
large effect on age-specific population estimates for some states 
and counties. Therefore, the national incidence and death rates 
were not affected, but some state-level rates were. The NCI also 
developed modifications to these Census population estimates that 
attempted to account at the county level for changes in population 
due to displacement of people after hurricanes Katrina and Rita in 
the most affected counties of Louisiana, Mississippi, Alabama, and 
Texas. 
 Second, we used two different statistical methods for two differ-
ent geographic sets of aggregate data to describe cancer trends: a 
single linear regression model to describe short-term trends 
(1996 – 2005) by race and ethnicity for geographic areas covering 
about two-thirds of the United States, and a joinpoint model to 
describe long-term trends (1975 – 2005) for all races and ethnicities 
combined in a subset of these geographic areas covering approxi-
mately one-tenth of the US population. The joinpoint model is 
preferable to single linear regression when a suffi cient number of 
years are available for analysis because it provides the opportunity 
to identify recent changes in magnitude and direction of trends, 
although the trends may be unstable when based on rates with 
large variance and statistical power is low for detecting joinpoint 
segments. Although enough years of data are now available to use 
joinpoint analysis for trends by race and ethnicity, we used single 
linear regression in this report for consistency with previous 
reports and because trends are presented for multiple sites and 
racial and ethnic groups. Methods have yet to be adapted for 
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 Figure 6 .  Initiation of smoking among 12- to 17-year-old adolescents in 
the United States by sex, 1940 – 2000. All calculations to determine the 
year in which respondents began smoking were based on the survey 
administration date in conjunction with responses given in the survey 
regarding initiation age of “regular” use and current age. Data are from 
the Tobacco Use Supplements to the Current Population Survey 
( 25 , 26 ). Means and 95% confi dence intervals ( error bars ) are shown. 
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delayed reporting of aggregated data, except for incidence from 
the nine oldest SEER registries. Delayed reporting may affect the 
most recent joinpoint segment for the national data. When join-
point analyses were applied to the fi xed interval period for aggre-
gated data based on SEER and NPCR, as reported by NAACCR, 
the results were generally similar to those based on the most recent 
10 years of data from the nine SEER registries (data not shown). 
 Third, the Veteran’s Health Administration (VA) hospitals 
have traditionally been a critical source of data for cancers that 
were diagnosed among veterans who are eligible to receive care 
from these facilities. In August 2007, the VA formally instituted 
new requirements and major restrictions for the submission of 
cancer cases to central cancer registries. Consequently, case 
reporting from VA facilities to central cancer registries dropped 
substantially after August 2007, primarily affecting incidence data 
for 2005. According to data from NCI ( http://seer.cancer.gov/
csr/1975_2005/resultsmerged/sect_33_VA_adjustment.pdf ), as a 
result of this change in case reporting, cancer incidence rates 
among men for 2005 in the 17 SEER registries that cover more 
than a quarter of the US population were underestimated by 
1.51% for all cancers combined and 2.33% and 1.18% for lung 
and prostate cancers, respectively ( 12 ). The amount of underesti-
mation based on data from other geographic areas may or may 
not be similar because of variation in VA reporting to central 
registries and in the VA’s proportionate contribution to the total 
number of cancers by state or geographic region. The NCI 
assessed the infl uence of missing VA cancer cases on the (report-
ing) delay-adjusted incidence trends in the nine oldest SEER 
registries. Recent trends in the incidence rates among men for all 
cancers combined, lung, colorectal, and prostate cancers using the 
joinpoint model after adjusting for missing VA cancer cases 
yielded results similar to those based on reporting delay-adjusted 
data ( 12 ). The impact of missing VA cases on future estimates of 
cancer incidence rates and trends may become greater as central 
registries fail to receive VA cancer cases. The VA cancers account 
for at least 3% and possibly as much as 8% of all cancers that were 
diagnosed in men that were available previously for reporting on 
national cancer statistics. 
 Fourth, analyses of trends in cancer rates and prevalence of 
smoking according to geographic areas (states or regions) could be 
affected by the characteristics of the 28 states for which trends in 
incidence can be measured and possibly by population mobility. 
The infl uence of migration on the rates and prevalence of smoking 
has less effect on large geographic areas (states or regions) than 
small areas (counties) ( 82 ). 
 Fifth, as routinely noted in the annual reports ( 7 – 10 ), the broad 
racial and ethnic groups that were categorized for our analyses may 
mask variations in the cancer burden by country of origin, eg, 
Chinese and Vietnamese in the group of API ( 83 ) and Cubans and 
Mexicans in the Hispanic category ( 9 , 84 ) or by other unique char-
acteristics of a variety of high-risk populations ( 10 , 82 – 88 ). 
Furthermore, cancer rates for populations other than white and 
black may be limited by problems in ascertaining race and ethnic-
ity information from basic records (medical records, death certifi -
cates, and census reports) ( 89 ). 
 Finally, estimates based on the CDC’s BRFSS data are limited 
because the survey relies exclusively on telephone interviews and 
response rates vary widely across states, with a median Council of 
the American Survey Research Organization response rate, which 
is the proportion of telephone numbers called that resulted in 
completed interviews, of 50% ( 90 , 91 ). Although state-specifi c 
smoking data are available from the TUS-CPS back to 1992 ( 25 ), 
we did not use them because they are not available for each year to 
estimate APC in smoking prevalence and because the most recent 
available year of data at the time of the preparation of this report 
was 2003. 
 Future Directions 
 The observed decrease in the incidence and death rates from all 
cancers combined in men and women overall and in nearly all racial 
and ethnic groups is highly encouraging. However, this must be 
seen as a starting point rather than a destination. A dual approach 
will be needed to sustain and extend this progress into the future. 
First, the application of existing knowledge must be improved so 
that evidence-based interventions reach all segments of the popula-
tion. Second, ongoing research is needed to improve our current 
methods of prevention, early detection, and treatment. 
 The special section of this report highlights geographic dispari-
ties in lung cancer, tobacco use, and tobacco control. Reductions 
in tobacco use provide the largest single opportunity to prevent 
nearly one-third of cancer deaths through the application of exist-
ing knowledge. State policies have an important infl uence on 
smoking initiation and cessation. Recent reports by the Institute of 
Medicine ( 92 ) and the CDC ( 75 ) document that states with com-
prehensive tobacco control programs experience more rapid 
decreases in per capita cigarette sales, smoking prevalence, and 
lung cancer than states without such programs ( 72 , 92 ). Despite 
this, most states underfund such programs ( 75 ). Although public 
health and advocacy initiatives have been increasingly effective in 
increasing tobacco excise taxes and enacting smoke-free laws, these 
efforts are offset by tobacco industry promotional activities, point-
of-sale discounts, and lobbying ( 92 ) and are threatened by recur-
rent budgetary constraints and efforts to reallocate tobacco excise 
tax funds away from tobacco and/or cancer control. 
 Policy approaches can discourage smoking initiation, encour-
age cessation, and protect nonsmokers from second-hand smoke at 
the population level. Complimenting these approaches are clinical 
guidelines to integrate evidence-based treatments for tobacco 
dependence into standard medical care ( 93 , 94 ) and ongoing 
research to improve cessation therapies ( 95 , 96 ), to identify genetic 
determinants of tobacco dependence ( 97 ), and to use these fi ndings 
in drug development ( 98 ). Randomized clinical trials are also 
testing whether the early detection of lung cancer by spiral 
computed tomography  reduces lung cancer mortality in high-risk 
groups ( 99 , 100 ) and whether novel targeted therapies are effective 
against certain subtypes of lung cancer ( 101 , 102 ). 
 Although cigarette smoking accounts for approximately 85% –
 90% of lung cancer deaths, the remaining 10% – 15% represent 
16  000 – 24  000 of the nearly 162  000 lung cancer deaths that have 
been projected to occur in 2008 ( 103 ). This number would rank 
among the 10 most common cancers in terms of deaths if consid-
ered as a separate category ( 104 ). Not all of these occur in lifelong 
nonsmokers because there is a background rate of lung cancers 
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that are caused by factors other than active smoking, even among 
current and former smokers. Research interest in lung cancer 
among never smokers has increased, however, partly because the 
molecular profi le of tumors and clinical response to targeted 
therapy differs for people who have never smoked than for smok-
ers ( 105 , 106 ), partly because the prevalence of current smoking 
continues to decrease, and partly because of media attention to this 
issue. 
 Although much progress can be achieved by more comprehen-
sively applying what we know about cancer causation, prevention, 
and treatment (eg, tobacco control, vaccination for Hepatitis B and 
human papillomavirus, chemoprevention of breast cancer in high-
risk groups, screening for colorectal cancer, and effective treat-
ments for several cancers), additional research is needed across the 
spectrum of cancer prevention, early detection, treatment, and pal-
liation. Further etiologic research is needed for cancer sites (eg, 
leukemia, NHL, myeloma, kidney, testicular, brain, and female 
thyroid cancers) at which incidence has increased and changes in 
detection and established risk factors may or may not fully explain 
the trends. Etiologic research is also needed for highly lethal can-
cers, such as pancreatic cancer, which is now the fourth leading site 
for cancer deaths in both men and women ( 103 ). Genome-wide 
association studies that involve examining genetic variation at typi-
cally hundreds of thousands of places along the genome of patients 
with specifi c diseases compared with control individuals have iden-
tifi ed promising genetic regions for further investigation for many 
diseases, including a region on chromosome 15 that have been 
associated with susceptibility to lung cancer ( 98 ). Better prognostic 
markers are needed to triage newly diagnosed cancers and to indi-
vidualize treatments to match the aggressiveness of the tumor 
( 107 ). The extensive research efforts needed to identify cancers 
early and develop personalized/targeted cancer therapies are 
beyond the scope of this report but involve better understanding of 
the genetic and epigenetic changes that occur within cells during 
progression to cancer, the molecular composition of cancer sub-
types, and gene expression and proteomic studies ( 98 , 107 – 109 ). 
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